Zacks Research Comments on Qiagen’s Q4 Earnings (NYSE:QGEN)

Qiagen N.V. (NYSE:QGEN) – Investment analysts at Zacks Research increased their Q4 2026 earnings per share estimates for Qiagen in a research report issued to clients and investors on Wednesday, February 25th. Zacks Research analyst Team now forecasts that the company will earn $0.66 per share for the quarter, up from their prior forecast of $0.63. The consensus estimate for Qiagen’s current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen’s Q1 2027 earnings at $0.67 EPS and Q4 2027 earnings at $0.77 EPS.

Several other equities research analysts have also issued reports on the stock. Citigroup lowered their target price on shares of Qiagen from $55.40 to $55.00 and set a “neutral” rating for the company in a report on Friday, February 6th. TD Cowen reissued a “hold” rating on shares of Qiagen in a research note on Friday, February 6th. Barclays set a $58.00 target price on Qiagen and gave the company an “overweight” rating in a research report on Friday, February 6th. UBS Group set a $52.00 price target on Qiagen in a report on Monday, February 9th. Finally, Jefferies Financial Group restated a “buy” rating and set a $59.00 price objective on shares of Qiagen in a report on Thursday, February 5th. Four investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Qiagen presently has a consensus rating of “Hold” and an average target price of $55.20.

Qiagen Stock Up 1.5%

NYSE QGEN opened at $49.81 on Monday. The company has a quick ratio of 3.31, a current ratio of 3.90 and a debt-to-equity ratio of 0.44. Qiagen has a 52 week low of $39.61 and a 52 week high of $57.81. The firm has a market capitalization of $10.52 billion, a price-to-earnings ratio of 24.71, a PEG ratio of 2.43 and a beta of 0.70. The company has a fifty day moving average of $50.01 and a two-hundred day moving average of $49.34.

Qiagen (NYSE:QGEN) last released its earnings results on Thursday, February 5th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.01. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The firm had revenue of $540.42 million for the quarter, compared to the consensus estimate of $528.53 million. During the same quarter in the previous year, the company posted $0.61 EPS. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year.

Institutional Investors Weigh In On Qiagen

Several hedge funds have recently made changes to their positions in QGEN. Danske Bank A S purchased a new position in shares of Qiagen during the third quarter valued at $36,000. Smartleaf Asset Management LLC grew its holdings in Qiagen by 1,383.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock worth $39,000 after acquiring an additional 830 shares in the last quarter. Manchester Capital Management LLC purchased a new position in Qiagen during the 4th quarter valued at about $42,000. MAI Capital Management raised its holdings in shares of Qiagen by 998.9% in the 2nd quarter. MAI Capital Management now owns 978 shares of the company’s stock valued at $47,000 after purchasing an additional 889 shares in the last quarter. Finally, Allworth Financial LP lifted its position in shares of Qiagen by 260.1% in the 2nd quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock worth $53,000 after purchasing an additional 796 shares during the period. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Qiagen News Roundup

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: DWS Investment disclosed a 2.76% voting stake in Qiagen — a notable institutional position that can lend support to the share price, raise confidence among other investors and prompt speculation about engagement or strategic influence. DWS Investment Discloses 2.76% Voting Stake in Qiagen
• Positive Sentiment: Reports show large volumes of Qiagen call options were purchased, indicating bullish positioning or short-term speculative interest that can amplify upward moves in the stock and attract momentum traders. Investors Buy Large Volume of Qiagen Call Options (NYSE:QGEN)
• Negative Sentiment: Zacks Research reduced EPS estimates across multiple near-term quarters and trimmed FY2026 and FY2027 forecasts (FY2026 cut from $2.57 to $2.51; FY2027 trimmed to $2.81 from $2.85), and lowered several quarterly estimates (Q1–Q3 2026 and Q2–Q3 2027). Those downgrades signal weaker near-term earnings growth expectations and could limit upside if revisions continue.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.